← Human Trials & Peer-Reviewed Studies
The growth hormone receptor exon 3-deleted/full-length polymorphism and response to growth hormone therapy in prepubertal idiopathic short children.
Plain-language guide to PMID 25742716 (2015): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length) in 167 children.
Key Facts
- PMID
- 25742716
- Journal
- Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
- Year
- 2015
- Study type
- Randomized Controlled Trial
- Authors
- Hellgren G et al. (5 authors)
- DOI
- 10.1016/j.ghir.2015.02.003
What This Study Did, in Plain Language
What Was Tested
Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length) in this randomized controlled trial publication.
The secondary aim was to investigate the impact of the GHR exon 3 deleted/full-length (d3/fl) polymorphism on GH treatment response in prepubertal children classified as having idiopathic short stature (ISS).
Who Took Part
According to the abstract, 167 children were involved.
The age groups tagged for this paper are infants, young children, children, teenagers, young adults and adults, both men and women.
Study subjects included 167 prepubescent longitudinally followed children classified as having ISS.
How the Study Was Run
The researchers set it up as a randomized study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Genotyping of the GHR d3/fl polymorphism was performed using TaqMan SNP genotyping of tagSNP rs6873545.
What Was Measured
The subject headings attached to it are Body Height, Case-Control Studies, Exons, Gene Deletion, Growth Disorders, Growth Hormone and Hormone Replacement Therapy.
Author keywords: Exon 3 deletion, Growth hormone receptor, Growth hormone treatment, Idiopathic short stature and Prepubertal children.
What This Means in Plain Language
The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and Thymosin Beta-4 (full length) in 167 children.
Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2015 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page and the Thymosin Beta-4 (full length) compound page, all human trials.
Our Notes on the Compounds
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Thymosin Beta-4 (full length): The natural 43-amino-acid actin-binding peptide behind the TB-500 name; tested in human trials for eye, skin-wound and heart conditions.
Related Pages
- Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library
- Thymosin Beta-4 (full length) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.